Ticagrelor

An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION.

Also Known As:

3-(7-((2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-(1-3)-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; AZD 6140; AZD-6140; AZD6140; Brilinta; Brilique; 1,2-cyclopentanediol, 3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-1,2,3-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)-

Networked: 2362 relevant articles (250 outcomes, 794 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Storey, Robert F: 127 articles (04/2022 - 11/2007)
2.	Angiolillo, Dominick J: 81 articles (11/2022 - 08/2008)
3.	Wallentin, Lars: 67 articles (04/2022 - 04/2009)
4.	Steg, Philippe Gabriel: 61 articles (12/2022 - 04/2009)
5.	Alexopoulos, Dimitrios: 57 articles (01/2022 - 07/2012)
6.	Cannon, Christopher P: 54 articles (08/2021 - 11/2007)
7.	Bhatt, Deepak L: 49 articles (12/2022 - 03/2013)
8.	James, Stefan K: 48 articles (12/2022 - 02/2011)
9.	Valgimigli, Marco: 41 articles (08/2022 - 08/2011)
10.	Husted, Steen: 41 articles (05/2017 - 05/2006)

Related Diseases

1.	Acute Coronary Syndrome 10/20/2014 - "Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. " 01/01/2019 - "Ticagrelor, in particular, has significantly improved the outcome in patients with acute coronary syndromes, offering potential benefits also in terms of survival. " 09/01/2010 - "The recently completed PLATO trial demonstrated promise for ticagrelor as a major treatment strategy for a wide spectrum of patients with acute coronary syndromes. " 02/17/2022 - "It remains unclear whether low-dose ticagrelor offers better safety and similar efficacy for Asian patients with acute coronary syndromes (ACS). " 06/01/2014 - "Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark."
2.	Hemorrhage 07/01/2023 - "During the follow-up period, there was a significant reduction in the incidence of ischemic events in patients treated using ticagrelor who had excessive risk of bleeding. " 11/03/2021 - "Diabetes management can be improved by carefully prescribing ticagrelor to individuals with low risk of bleeding and high risk of ischaemic events." 09/05/2018 - "Among real-world Chinese patients with ACS treated by PCI, ticagrelor only showed superior efficacy in patients with low bleeding risk but lost its advantage in patients with moderate-to-high bleeding potential. " 09/05/2018 - "We considered that the baseline bleeding risk might be an undetected key factor that significantly affected the efficacy of ticagrelor. " 01/01/2022 - "We systematically identified new genetic variants and some risk factors for reduced efficacy of ticagrelor and highlighted related genes that may be involved in antiplatelet effects and bleeding event of ticagrelor. "
3.	ST Elevation Myocardial Infarction 01/01/2020 - " Use of GPIs in addition to ticagrelor in STEMI patients was not associated with an improvement in 30-day ischemic outcome. " 01/01/2023 - "This trial included 374 STEMI patients with a low platelet response after ticagrelor LD. " 05/01/2020 - "Safety and Cumulative Incidence of Major Cardiovascular Events with Ticagrelor in Taiwanese Patients with Non-ST-Segment Elevation Myocardial Infarction: A 12-Month, Prospective, Phase IV, Multicenter, Single-Arm Study." 01/01/2020 - "The ATLANTIC study compared prehospital versus inhospital treatment with ticagrelor in patients with acute STEMI. " 04/01/2019 - "ATLANTIC was an international, multicenter, randomized study of treatment in the acute ambulance/hospital setting where STEMI patients received ticagrelor 180 mg ± morphine. "
4.	Myocardial Infarction 01/01/2021 - "However, a significant reduction of recurrent myocardial infarction was observed with ticagrelor." 04/07/2016 - "Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54." 01/01/2023 - "Conclusions Using a natural experiment, this study finds that the implementation and use of ticagrelor in routine clinical care has reduced 12-month mortality in patients admitted to the hospital with myocardial infarction in Sweden and supports the external validity of randomized evidence on ticagrelor effectiveness." 01/01/2023 - "The aim of this study was to estimate the effect of implementing and using ticagrelor in routine clinical care in patients with myocardial infarction using a natural experimental approach. " 12/01/2021 - "Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial."
5.	Stroke (Strokes) 01/01/2018 - "Even though ticagrelor was beneficial in prior cardiovascular trials, its efficacy in stroke prevention was inconclusive in recent randomized-controlled clinical trials (RCTs). " 01/01/2021 - "Ticagrelor may be beneficial in preventing post-MI stroke in East Asian patients." 09/20/2016 - "We investigated the incidence of stroke, outcomes after stroke, and the efficacy of ticagrelor focusing on the approved 60 mg twice daily dose for reducing stroke in this population. " 04/15/2022 - "In recent randomized controlled studies, the prevention of stroke and cognitive function of ticagrelor has been controversial. " 01/01/2021 - "These patients were included in the Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial, but results have not been reported separately, raising concerns about safety and efficacy in this subgroup. "

Related Drugs and Biologics

1.	Clopidogrel (Plavix)
2.	Prasugrel Hydrochloride
3.	Aspirin (Acetylsalicylic Acid)
4.	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))
5.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
6.	Cytochrome P-450 CYP2C19
7.	omega-Chloroacetophenone (Mace)
8.	cangrelor
9.	Morphine (MS Contin)
10.	Purinergic P2Y Receptor Antagonists

Related Therapies and Procedures

1.	Therapeutics
2.	Percutaneous Coronary Intervention
3.	Stents
4.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
5.	Thrombolytic Therapy